Clinical trial NCT06087991: Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment
Official title: Buprenorphine Induction and Naloxone Distribution Program-Combined With Warm Hand-Off Referral to Continued Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Opioid Abuse
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2023-10-18
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 25 qualitative interviews of Castleview providers and stakeholders; 337 Castleview patient participants given buprenorphine and naloxone kits

Brief summary: This study is a collaboration between the University of Utah and Castleview Hospital in Price, Utah.

Buprenorphine is a medication approved by the FDA to treat Opioid Use Disorder (OUD). Castleview Hospital currently does not prescribe buprenorphine in the emergency department (ED) instead it refers patients to outside addiction treatment facilities. This is a service focused project which the University of Utah will provide mentoring and education to Castleview in implementing an in ED buprenorphine/naloxone distribution program along with referral to continued services. After the program has been implemented, the investigators will evaluate it using quantitative surveys of program participants and qualitative interviews of hospital staff and stakeholders.

Detailed description: Among health care environments, ED often are the front lines of care for those with OUD or who experience opioid overdose.

The University of Utah Hospital ED has the Bridge Program which provides buprenorphine and naloxone with warm-hand off referral for continued treatment to people presenting with OUD. In order to extend the services offered by the Bridge Program to rural hospitals, the investigators will be providing mentoring and education to Castleview Hospital in establishing a similar program. Castleview Hospital is the only acute care hospital that serves Carbon and Emery counties, which outside of the Salt Lake City metro area have the highest opioid overdose rates in the State of Utah.

This project will utilize both quantitative and qualitative measures to evaluate the impact of this program on patients, hospital staff, and community members.

Eligibility criteria: Inclusion Criteria:

For qualitative interviews with providers, administrators, stakeholders:

* Must be affiliated with Castleview Hospital as a provider, administrator or stakeholder.

For the quantitative surveys:

* Must be a Castleview Hospital patient who receives the BINDeR-Tx model.

Exclusion Criteria:

For qualitative interviews with providers, administrators, stakeholders:

* Not familiar with the BINDeR-Tx model
* No interaction with the BINDeR-Tx model

For the quantitative surveys:

* Unable to speak and read English
* Subject is unable to provide contact information

Primary outcomes:
measure: Patient Focused: Number of patients receiving services.
timeFrame: 24 months
Secondary outcomes:
measure: Implementation and service quality: Satisfaction with projected service
timeFrame: 24 months.
measure: Implementation and service quality: Patient satisfaction
timeFrame: enrollment and 6 months post enrollment
measure: Substance use diagnosis and treatment
timeFrame: enrollment and 6 months post enrollment
measure: Social Connectedness
timeFrame: enrollment and 6 months post enrollment
measure: Living Conditions
timeFrame: enrollment and 6 months post enrollment
measure: Mental and Physical Health Problems and Treatment/Recovery
timeFrame: enrollment and 6 months post enrollment
measure: Legal Status
timeFrame: enrollment and 6 months post enrollment
measure: Discharge status
timeFrame: enrollment and 6 months post enrollment
measure: Follow-up Status
timeFrame: enrollment and 6 months post enrollment
measure: Education, Employment, and Income
timeFrame: enrollment and 6 months post enrollment
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: University of Utah
state: Utah
Study officials:
affiliation: University of Utah
name: Jerry Cochran
role: PRINCIPAL_INVESTIGATOR
References: